Latest Articles

Opdivo in Head and Neck Cancer Represents New Hope and the Culmination of a Career
BY LAURA PANJWANI
"This is what I've devoted my career to, and it is gratifying to see that really come to pass," says Robert Ferris.
Immunotherapy and Radiation Combo Boosts Survival in Melanoma Patients With Brain Metastases
BY LAURA PANJWANI
The combination of Opdivo and radiation therapy may provide better disease control and a boost in overall survival in patients with melanoma whose disease has metastasized to the brain.
A Christmas Angel for Those of Us With Cancer
BY BEN HOLMAN
An essay from our Extraordinary Healers book honoring Sharon Bernico, RN, OCN [Oncology Therapy Center in Morris, Illinois].
New Therapy Shows Early Promise, Continues to Progress in Triple-Negative Breast Cancer
BY JASON M. BRODERICK
The designation, which will expedite the development and review of sacituzumab govitecan in TNBC, is based on a phase 2 trial in which the therapy induced a response rate of 31 percent in heavily pretreated patients with metastatic TNBC.
Inspiring Others to Make a Difference in the Life of Someone With Cancer
BY SANDRA SHELTON, RN
Finalist for the 2015 Extraordinary Healer Award for Oncology Nursing: Elmeria S. Teffeteller, RN, MSN, APRN, AOCN, University of Tennessee Cancer Institute in Knoxville, Tennessee
American Society of Clinical Oncology Names Immunotherapy
BY GINA COLUMBUS
"No recent cancer advance has been more transformative than immunotherapy," said ASCO president Julie M. Vose.
Physician Says Ninlaro Approval Represents
BY LAURA PANJWANI
In an interview with CURE, Philippe Moreau discusses the significance of Ninlaro's approval and the TOURMALINE-MM1 study.
On World Cancer Day, UICC Asks for Help in Reducing Global Burden of Cancer
BY ANDREW J. ROTH
Held each year on Feb. 4, World Cancer Day aims to unite people from around the world to increase awareness of cancer in a positive and inspiring way.
FDA Approves Single-Dose Emend for Injection for CINV
BY JASON M. BRODERICK
The approval is primarily based on the phase 3 MK-0517-031 study, in which adding single-dose Emend for injection induced a complete response in nearly 80 percent of patients receiving MEC.
$auto_registration$